A novel curcumin derivative, C210, activates the Epstein–Barr virus (EBV) lytic cycle without producing infectious virions by disrupting HSP90. This discovery opens avenues for safer EBV-positive cancer therapies.
GSK’s new cancer drug Jemperli (dostarlimab) won an FDA approval on Monday, almost two months ahead of its PDUFA date, for use in certain frontline
Health care providers have a sacrosanct relationship with patients. That unique position of trust also puts them in a position of power over their patients.